
Temitayo Ogunleye
Professor of Clinical Dermatology at the University of Pennsylvania Perelman School of Medicine and skin of color expert.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
Oct 2, 2026
Common Dermatologic Conditions with Dr. Temitayo Ogunleye
11:20
11:37
11:45
11:53
12:00
12:03

Amanda SwainHOST
But in terms of a general approach to someone with atopic dermatitis, how do you start to think through how intensive a therapy does this person need and when would you potentially advance their therapy?

Temitayo OgunleyeGUEST
It's partially based on symptoms and how much is affecting the patient and also total body surface area involvement.

Temitayo OgunleyeGUEST
We usually say that if you have less than 10% total body surface area involvement, then you can usually get away with topical therapy.

Temitayo OgunleyeGUEST
But once you get above 10%, it becomes a little bit more onerous, a little bit more difficult to do topical therapy reliably.

Temitayo OgunleyeGUEST
And then I would say, as I said, the other part is how much it's affecting a patient.

Temitayo OgunleyeGUEST
So for instance, a patient can have very little body surface area involvement, but have involvement on the face or have involvement in the hands where it's affecting function, affecting, you know, their quality of life.
15 MINS LATER